Accès gratuit
Volume 64, Numéro 3, Mai-Juin 2009
Page(s) 187 - 194
Section Méthodologie/Methodology
Publié en ligne 13 août 2009
  1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95 [Google Scholar]
  2. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3): 719-26 [Google Scholar]
  3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-92 [Google Scholar]
  4. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23 (19): 4265-74 [Google Scholar]
  5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1659-72 [Google Scholar]
  6. Penault-Llorca F, Balaton A, Sabourin JC, et al. Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines. Ann Pathol 2002; 22 (2): 150-7 [Google Scholar]
  7. Phillips AK, Van Bebber S, Isssa AM. Diagnostics and biomarker development: priming the pipeline. Nature Reviews Drug Disccovery 2006; 5: 463-69 [CrossRef] [Google Scholar]
  8. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 (8): 3992-5 [Google Scholar]
  9. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 (10): 1626-34 [Google Scholar]
  10. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 2 [Google Scholar]
  11. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359 (17): 1757-6. [Google Scholar]
  12. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9 (10): 962-72 [Google Scholar]
  13. Picard S, Titier K, Etienne G, et al. Through imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109 (8): 3496-9 [Google Scholar]
  14. Tuma RS. Disease progression in some cancers may be due to low blood levels of targeted therapies. J Natl Cancer Inst 2008; 100 (13): 912-3 [Google Scholar]
  15. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90 (6): 2188-95 [Google Scholar]
  16. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13 (6): 928-43 [Google Scholar]
  17. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358 (11): 1109-17 [Google Scholar]
  18. Vray M, Girault D, Hoog-Labouret N, et al. Méthodologie des essais cliniques de petits effectifs. Therapie 2004; 59 (3): 273-9 [Google Scholar]